Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Feracrylum is a synthetic polyacrylic polymer used as a topical hemostatic and antiseptic agent. It is primarily indicated for the control of bleeding in wounds, burns, post-operative sites, dental extractions, and oral surgeries. Feracrylum acts by forming a complex with albumin and other blood proteins at the site of application, creating a physical barrier that promotes rapid clot formation within 2–3 minutes. Its mechanism involves activation of thrombin (factor IIa), which converts fibrinogen to fibrin to stabilize clots. Additionally, feracrylum exhibits antimicrobial activity against gram-positive and gram-negative bacteria as well as fungi, reducing infection risk in treated wounds. Its hygroscopic properties help maintain moisture at the wound site for faster healing and easier dressing removal[1][2][4][5][6][7][8]. Developers: Themis Medicare
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on feracrylum.